Y. Y. Janjigian Et Al. , "Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study," Annual Meeting of the Society-of-Surgical-Oncology (SSO) , Georgia, United States Of America, 2024
Janjigian, Y. Y. Et Al. 2024. Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. Annual Meeting of the Society-of-Surgical-Oncology (SSO) , (Georgia, United States Of America).
Janjigian, Y. Y., Al-Batran, S., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., ... Hyung, W. J.(2024). Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study . Annual Meeting of the Society-of-Surgical-Oncology (SSO), Georgia, United States Of America
Janjigian, Yelena Et Al. "Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study," Annual Meeting of the Society-of-Surgical-Oncology (SSO), Georgia, United States Of America, 2024
Janjigian, Yelena Y. Et Al. "Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study." Annual Meeting of the Society-of-Surgical-Oncology (SSO) , Georgia, United States Of America, 2024
Janjigian, Y. Y. Et Al. (2024) . "Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study." Annual Meeting of the Society-of-Surgical-Oncology (SSO) , Georgia, United States Of America.
@conferencepaper{conferencepaper, author={Yelena Y. Janjigian Et Al. }, title={Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study}, congress name={Annual Meeting of the Society-of-Surgical-Oncology (SSO)}, city={Georgia}, country={United States Of America}, year={2024}}